Data analysis puts the efficacy of molnupiravir in reducing the risk of hospitalisation and death from COVID-19 at around 20% lower than originally believed
New data on the efficacy of Lagevrio (molnupiravir) in reducing the risk of hospitalisation and death from COVID-19 show that the efficacy is lower than initially thought. The European Medicines Agency (EMA) has started reviewing the new data, which show a reduction of efficacy of about 20%.
Recommendations issued by the EMA in November were based on an assessment of interim data from a study, which were available at the time of the review. Those results indicated that the reduced the risk of hospitalisation or death in people with COVID-19 who were at higher risk of severe disease from 14.1% in the placebo group to 7.3% in the molnupiravir group, a 50% decrease in risk.
Based on these figures, the EMA advised that the medicine, which is currently not authorised in the EU, could be used to treat adults with COVID-19 who do not require supplemental oxygen, and who are at increased risk of developing severe COVID-19.
However, the latest data show a less dramatic reduction. The updated results, based on 1408 subjects, show that molnupiravir reduced the risk of hospitalisation or death by 6.8% compared to 9.7% in the placebo group, a decrease of just 30%.
Molnupiravir is the first oral medicine for non-hospitalised patients with mild-to-moderate COVID-19. It is currently being evaluated for inclusion in the World Health Organization’s living guideline on COVID-19 therapeutics.
This article originally appeared on Medscape, part of the Medscape Professional Network.
Lead image: sdecoret/stock.adobe.com
Image 1: sdecoret/stock.adobe.com